Chronic Kidney Disease Ckd Pipeline Insight

DelveInsight’s, “Chronic Kidney Disease (CKD) – Pipeline Insights, 2022,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Chronic Kidney Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Chronic Kidney Disease Understanding

Chronic Kidney Disease (CKD): Overview

Chronic Kidney Disease is a condition in which kidneys are damaged and cannot filter blood. As a result, extra fluid and waste from the blood remain in the body, potentially leading to various health issues like heart disease and stroke. Chronic Kidney Disease has various levels of seriousness. It usually gets worse with time though treatment has been shown to slow progression. If left untreated, CKD can progress to kidney failure and early cardiovascular disease. People with chronic kidney disease may not feel ill or notice any symptoms. CKD signs and symptoms develop over time if kidney damage progresses slowly. Loss of kidney function can cause a buildup of fluid or body waste or electrolyte problems. The most common symptoms of chronic kidney disease include: hypertension, anemia, edema, fatigue, decreased urine output, blood in urine, dark urine, loss of appetite and persistent itchy skin. Patients feel unwell or have symptoms with mild-to-moderate chronic kidney disease that is, stages 1 to 3. Chronic kidney disease is usually diagnosed by the eGFR test before any symptoms develop. Symptoms tend to develop when chronic kidney disease becomes severe (stage 4) or worse. The symptoms at first tend to be vague and nonspecific, such as feeling tired, having less energy than usual and just not feeling well. The most common cause of chronic kidney disease is diabetes and high blood pressure. Each kidney contains about 1 million tiny filtering units, called nephrons. Any disease that injures or scars the nephrons can cause kidney disease. Diabetes and high blood pressure can both damage the nephrons. High blood pressure can also damage the blood vessels of your kidneys, heart, and brain. The kidneys are highly vascularized, meaning they contain lots of blood vessels. So, blood vessel diseases are generally dangerous to your kidneys. If uncontrolled, or poorly controlled, high blood pressure can be a leading cause of heart attacks, strokes and chronic kidney disease. Also, chronic kidney disease can cause high blood pressure. Chronic kidney disease (CKD) has no cure, but treatment can help relieve symptoms and prevent it from worsening. While the damage to your kidneys cannot be reversed, precautions to maintain them as healthy for as long as possible. The treatment will depend on the stage of CKD.

 

“Chronic Kidney Disease- Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Kidney Disease pipeline landscape is provided which includes the disease overview and Chronic Kidney Disease treatment guidelines. The assessment part of the report embraces, in depth Chronic Kidney Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Kidney Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Kidney Disease R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Kidney Disease.

Chronic Kidney Disease Emerging Drugs Chapters

This segment of the Chronic Kidney Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Chronic Kidney Disease Emerging Drugs

 

KBP-5074: KBP Biosciences

KBP Biosciences’ lead product candidate, KBP-5074, is a potentially best-in-class, next-generation, non-steroidal MRA discovered and developed by KBP’s scientists, is being developed globally to initially treat Stage 3b/4, or moderate-to-severe, CKD patients with uncontrolled hypertension. KBP-5074 selectively binds to recombinant human MRs with much higher affinity than to recombinant human glucocorticoid, progesterone, and androgen receptors, suggesting that KBP-5074 should be effective in blocking the hypertensive and renal tissue damaging effects of aldosterone with reduced risk of pro-diabetic and adverse endocrine effects. In clinical trials conducted to-date, it has demonstrated an ability to lower blood pressure without androgenic effects such as hirsutism, obesity and gynecomastia. The drug is currently being evaluated in Phase III stage of development for the treatment of patients with Uncontrolled Hypertension and Moderate or Severe CKD.

 

Empagliflozin: Boehringer Ingelheim/Eli Lilly and Company

Empagliflozin (BI10773) is a chemical entity that inhibits the sodium glucose co-transporter-2 (SGLT 2). BI10773 is being studied in collaboration with Boehringer Ingelheim as a treatment for chronic kidney disease.

 

ALLN-346: Allena Pharmaceuticals

ALLN-346 is an investigational first-in-class, non-absorbed, orally administered enzyme for the treatment of hyperuricemia and gout, a metabolic disorder characterized by high systemic levels of urate that can lead to several complications, including arthritis, kidney stones, and CKD.

 

US-APR2020: Kibow Pharma

US-APR2020 is a natural probiotics formulation that metabolizes nitrogenous waste, which generally diffuses from the circulating bloodstream into the bowel. When these waste products accumulate in high concentrations in the blood, they become highly toxic and can cause severe damage to many organ systems if they are not properly excreted. US-APR2020 utilizes nitrogenous wastes as nutrients. As probiotics grow and multiply, they consume more nitrogenous waste and effectively maintain healthy kidney function.

 

MEDI8367: AstraZeneca

Medi8367 is an antibody which is used to treat Chronic Kidney Disease. It specifically binds human integrin β8 and works allosterically reducing its affinity for the LAP domain, hence preventing β8-mediated TGFβ activation but not its cell adhesion function.

Further product details are provided in the report……..

Chronic Kidney Disease: Therapeutic Assessment

This segment of the report provides insights about the different Chronic Kidney Disease drugs segregated based on following parameters that define the scope of the report, such as:

 

Major Players in Chronic Kidney Disease

There are approx. 50+ key companies which are developing the therapies for Chronic Kidney Disease. The companies which have their Chronic Kidney Disease drug candidates in the most advanced stage, i.e. phase III include, KBP Biosciences.

 

Phases

DelveInsight’s report covers around 50+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Route of Administration

Chronic Kidney Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

 

Molecule Type

Products have been categorized under various Molecule types such as

  • Oligonucleotide
  • Peptide
  • Small molecule

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chronic Kidney Disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic Kidney Disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Kidney Disease drugs.

Report Highlights

  • The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Kidney Disease R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Kidney Disease.
  • August 2020: DAPA-CKD trial meets primary endpoint in patients with chronic kidney disease. Dapagliflozin reduces the risk of kidney failure, death from cardiovascular causes or heart failure hospitalisation and all-cause mortality in chronic kidney disease patients with or without type 2 diabetes. That’s the main result of the DAPA-CKD trial presented in a Hot Line session today at ESC Congress 2020.

Chronic Kidney Disease Report Insights

  • Chronic Kidney Disease Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Chronic Kidney Disease Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Chronic Kidney Disease drugs?
  • How many Chronic Kidney Disease drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Kidney Disease?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chronic Kidney Disease therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Chronic Kidney Disease and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • AdAlta Ltd
  • Allena Pharmaceuticals Inc
  • apceth Biopharma GmbH
  • Arch Biopartners Inc
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • Bayer AG
  • BiOrion Technologies BV
  • Boehringer Ingelheim GmbH
  • Boryung Pharmaceutical Co Ltd
  • Celgene Corp
  • Certa Therapeutics Pty Ltd
  • Conatus Pharmaceuticals Inc
  • Corvidia Therapeutics Inc
  • DiaMedica Therapeutics Inc
  • Dimerix Bioscience Pty Ltd
  • DiscoveryBiomed Inc
  • DURECT Corp
  • Epigen Biosciences Inc
  • Galectin Therapeutics Inc
  • GenKyoTex SA
  • GNI Group Ltd
  • iBio Inc
  • IC-MedTech Inc
  • Ipsen SA
  • Isarna Therapeutics GmbH
  • KBP BioSciences Co Ltd
  • Kidney Fibrosis
  • Klotho Therapeutics Inc
  • Les Laboratoires Servier SAS
  • ManRos Therapeutics
  • Mironid Ltd
  • NovaTarg Therapeutics Inc
  • Novo Nordisk AS
  • OPKO Health Inc
  • Opsidio LLC
  • Otsuka Holdings Co Ltd
  • Pharmaxis Ltd
  • Q BioMed Inc
  • Redx Pharma Plc
  • Regulus Therapeutics Inc
  • Resverlogix Corp
  • Sanwa Kagaku Kenkyusho Co Ltd
  • Sarfez Pharmaceuticals Inc
  • Scholar Rock Inc
  • Sirnaomics Inc
  • Sphaera Pharma Pte Ltd
  • Symic Biomedical Inc
  • Taisho Pharmaceutical Holdings Co Ltd
  • Theravance Biopharma Inc
  • Unity Biotechnology Inc
  • Vascular Biogenics Ltd
  • Vascular BioSciences
  • VESSL Therapeutics Ltd
  • Vicore Pharma AB

Key Products

  • AZD5718
  • MEDI8367
  • efepoetin alfa
  • Verinurad
  • Empagliflozin
  • DDO-3055
  • KBP-5074
  • Doxercalciferol
  • TRC101
  • Pegol-Sihematide

Introduction

Executive Summary

Chronic Kidney Disease: Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Chronic Kidney Disease– DelveInsight’s Analytical Perspective

Late Stage Products (Pre-Registration)

  • Comparative Analysis

Drug Name : Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Last Stage Products (Phase III)

  • Comparative Analysis

KBP-5074: KBP Biosciences

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

  • Comparative Analysis

ALLN-346: Allena Pharmaceuticals

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

  • Comparative Analysis

MEDI8367: AstraZeneca

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Chronic Kidney Disease Key Companies

Chronic Kidney Disease Key Products

Chronic Kidney Disease - Unmet Needs

Chronic Kidney Disease - Market Drivers and Barriers

Chronic Kidney Disease - Future Perspectives and Conclusion

Chronic Kidney Disease Analyst Views

Chronic Kidney Disease Key Companies

Appendix

List of Tables

 Table 1 Total Products for Chronic Kidney Disease

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List of Figures

 Figure 1 Total Products for Chronic Kidney Disease

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

• KBP Biosciences
• Eli Lilly and Company
• Novo Nordisk
• Prokidney
• Boryung Pharmaceutical
• Boehringer Ingelheim
• Cadila Healthcare Limited
• AM-Pharma
• DiaMedica Therapeutics
• Allena Pharmaceuticals
• AstraZeneca
• Kibow Pharma
• Bayer
• Roche
• Caladrius Biosciences
• UnicoCell Biomed
• Scohia Pharma
• Unicycive Therapeutics
• Senda Biosciences
• Sarfez Pharmaceuticals
• Rege Nephro
• Orgenesis
• Oisin Biotechnologies
• Aria Pharmaceuticals
• RedHill Biopharma
• BERGENBIO
• GNI Group

 

Forward to Friend

Need A Quote